Noncoding RNAs in diabetes vascular complications

Journal of Molecular and Cellular Cardiology

Volumn 89, Issue , 2015, Pages 42-50

  Beltrami, Cristina ^a   Angelini, Timothy G ^b   Emanueli, Costanza ^a,c  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Biomarkers; Bone marrow derived cells; Diabetes; Extracellular vesicles; Long noncoding RNAs; MicroRNAs; Vascular cells

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENTARY RNA; LONG UNTRANSLATED RNA; MICRORNA; UNTRANSLATED RNA;

BONE MARROW CELL; CELL VACUOLE; CELLS BY BODY ANATOMY; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIABETIC ANGIOPATHY; DISEASE ASSOCIATION; DOWN REGULATION; EXTRACELLULAR SPACE; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; GENETIC REGULATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; UPREGULATION; VASCULAR CELL; ANIMAL; ENDOTHELIUM CELL; GENETICS; METABOLISM; TRANSLATIONAL RESEARCH;

ANIMALS; DIABETIC ANGIOPATHIES; ENDOTHELIAL CELLS; HUMANS; MICRORNAS; RNA, LONG NONCODING; RNA, UNTRANSLATED; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84952668046     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.12.014     Document Type: Review

References (117)

1. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2005, 28(Suppl. 1):S37-S42.
2. World Health Organization Global health risks: mortality and burden of disease attributable to selected major risks 2009.
3. Tricco A.C., Ivers N.M., Grimshaw J.M., Moher D., Turner L., Galipeau J., et al. Effectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysis. Lancet 2012, 379:2252-2261.
4. Rosenson R.S., Fioretto P., Dodson P.M. Does microvascular disease predict macrovascular events in type 2 diabetes?. Atherosclerosis 2011, 218:13-18.
5. Cheung N., Mitchell P., Wong T.Y. Diabetic retinopathy. Lancet 2010, 376:124-136.
6. Tabit C.E., Chung W.B., Hamburg N.M., Vita J.A. Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. Rev Endocr Metab Disord 2010, 11:61-74.
7. Spinetti G., Kraenkel N., Emanueli C., Madeddu P. Diabetes and vessel wall remodelling: from mechanistic insights to regenerative therapies. Cardiovasc Res 2008, 78:265-273.
8. Howangyin K.Y., Silvestre J.-S. Diabetes mellitus and ischemic diseases: molecular mechanisms of vascular repair dysfunction. Arterioscler Thromb Vasc Biol 2014, 34:1126-1135.
9. Fadini G.P., Ferraro F., Quaini F., Asahara T., Madeddu P. Concise review: diabetes, the bone marrow niche, and impaired vascular regeneration. Stem Cells Transl Med 2014, 3:949-957.
10. Silvain J., Vignalou J.-B., Barthélémy O., Kerneis M., Collet J.-P., Montalescot G. Coronary revascularization in the diabetic patient. Circulation 2014, 130:918-922.
11. Chung J., Modrall J.G., Valentine R.J. The need for improved risk stratification in chronic critical limb ischemia. J Vasc Surg 2014, 60(6):1677-1685.
12. Becker F., Robert-Ebadi H., Ricco J.-B., Setacci C., Cao P., de Donato G., et al. Chapter I: definitions, epidemiology, clinical presentation and prognosis. Eur J Vasc Endovasc Surg 2011, 42(Suppl. 2):S4-S12.
13. Djebali S., Davis C.A., Merkel A., Dobin A., Lassmann T., Mortazavi A., et al. Landscape of transcription in human cells. Nature 2012, 489:101-108.
14. Derrien T., Johnson R., Bussotti G., Tanzer A., Djebali S., Tilgner H., et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res 2012, 22:1775-1789.
15. Shantikumar S., Caporali A., Emanueli C. Role of microRNAs in diabetes and its cardiovascular complications. Cardiovasc Res 2012, 93:583-593.
16. Caporali A., Emanueli C. MicroRNA regulation in angiogenesis. Vascul Pharmacol 2011, 55:79-86.
17. Kim V.N., Han J., Siomi M.C. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 2009, 10:126-139.
18. Winter J., Jung S., Keller S., Gregory R.I., Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009, 11:228-234.
19. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
20. Tétreault N., De Guire V. miRNAs: their discovery, biogenesis and mechanism of action. Clin Biochem 2013, 46:842-845.
21. Yi R. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 2003, 17:3011-3016.
22. Kim V.N. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 2005, 6:376-385.
23. Lee Y., Ahn C., Han J., Choi H., Kim J., Yim J., et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003, 425:415-419.
24. Finnegan E.F., Pasquinelli A.E. MicroRNA biogenesis: regulating the regulators. Crit Rev Biochem Mol Biol 2013, 48:51-68.
25. Chendrimada T.P., Gregory R.I., Kumaraswamy E., Norman J., Cooch N., Nishikura K., et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nat Cell Biol 2005, 436:740-744.
26. Bang C., Batkai S., Dangwal S., Gupta S.K., Foinquinos A., Holzmann A., et al. Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J Clin Invest 2014, 124:2136-2146.
27. Condorelli G., Latronico M.V.G., Dorn G.W. microRNAs in heart disease: putative novel therapeutic targets?. Eur Heart J 2010, 31:649-658.
28. van Rooij E., Olson E.N. MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 2007, 117:2369-2376.
29. Bauersachs J., Thum T. Biogenesis and regulation of cardiovascular microRNAs. Circ Res 2011, 109:334-347.
30. Hausser J., Zavolan M. Identification and consequences of miRNA-target interactions-beyond repression of gene expression. Nat Rev Genet 2014, 15:599-612.
31. Ørom U.A., Nielsen F.C., Lund A.H. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell 2008, 30:460-471.
32. Eiring A.M., Harb J.G., Neviani P., Garton C., Oaks J.J., Spizzo R., et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell 2010, 140:652-665.
33. Gu S., Kay M.A. How do miRNAs mediate translational repression?. Silence 2010, 1:11.
34. Wu L., Belasco J.G. Let me count the ways: mechanisms of gene regulation by miRNAs and siRNAs. Mol Cell 2008, 29:1-7.
35. Voellenkle C., Rooij J.V., Guffanti A., Brini E., Fasanaro P., Isaia E., et al. Deep-sequencing of endothelial cells exposed to hypoxia reveals the complexity of known and novel microRNAs. RNA 2012, 18:472-484.
36. Thum T., Gross C., Fiedler J., Fischer T., Kissler S., Bussen M., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008, 456:980-984.
37. Peacock O., Lee A.C., Cameron F., Tarbox R., Vafadar-Isfahani N., Tufarelli C., et al. Inflammation and MiR-21 pathways functionally interact to downregulate PDCD4 in colorectal cancer. PLoS One 2014, 9:e110267.
38. Wang J.-Y., Gao Y.-B., Zhang N., Zou D.-W., Xu L.-P., Zhu Z.-Y., et al. Tongxinluo ameliorates renal structure and function by regulating miR-21-induced epithelial-to-mesenchymal transition in diabetic nephropathy. AJP: Renal Physiol 2014, 306:F486-F495.
39. Gatsiou A., Boeckel J.-N., Randriamboavonjy V., Stellos K. MicroRNAs in platelet biogenesis and function: implications in vascular homeostasis and inflammation. Curr Vasc Pharmacol 2012, 10:524-531.
40. Nohata N., Hanazawa T., Enokida H., Seki N. microRNA-1/133a and microRNA-206/133b clusters: dysregulation and functional roles in human cancers. Oncotarget 2012, 3:9-21.
41. Zampetaki A., Kiechl S., Drozdov I., Willeit P., Mayr U., Prokopi M., et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010, 107:810-817.
42. Zhong X., Chung A.C.K., Chen H.Y., Dong Y., Meng X.M., Li R., et al. miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia 2013, 56:663-674.
43. Feng B., Chen S., George B., Feng Q., Chakrabarti S. miR133a regulates cardiomyocyte hypertrophy in diabetes. Diabetes Metab Res Rev 2010, 26:40-49.
44. Chen S., Puthanveetil P., Feng B., Matkovich S.J., Dorn G.W., Chakrabarti S. Cardiac miR-133a overexpression prevents early cardiac fibrosis in diabetes. J Cell Mol Med 2014, 18:415-421.
45. Elia L., Quintavalle M., Zhang J., Contu R., Cossu L., Latronico M.V.G., et al. The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ 2009, 16:1590-1598.
46. Riches K., Alshanwani A.R., Warburton P., O'Regan D.J., Ball S.G., Wood I.C., et al. Elevated expression levels of miR-143/5 in saphenous vein smooth muscle cells from patients with type 2 diabetes drive persistent changes in phenotype and function. J Mol Cell Cardiol 2014, 74:240-250.
47. Ohnaka M., Marui A., Yamahara K., Minakata K., Yamazaki K., Kumagai M., et al. Effect of microRNA-145 to prevent vein graft disease in rabbits by regulation of smooth muscle cell phenotype. J Thorac Cardiovasc Surg 2014, 148:676-82.e2.
48. Sala F., Aranda J.F., Rotllan N., Ramírez C.M., Aryal B., Elia L., et al. MiR-143/145 deficiency attenuates the progression of atherosclerosis in Ldlr-/- mice. Thromb Haemost 2014, 112:796-802.
49. Wang X.H., Qian R.Z., Zhang W., Chen S.F., Jin H.M., Hu R.M. MicroRNA-320 expression in myocardial microvascular endothelial cells and its relationship with insulin-like growth factor-1 in type 2 diabetic rats. Clin Exp Pharmacol Physiol 2009, 36:181-188.
50. Lewis B.P., Shih I.-H., Jones-Rhoades M.W., Bartel D.P., Burge C.B. Prediction of mammalian microRNA targets. Cell 2003, 115:787-798.
51. Caporali A., Meloni M., Völlenkle C., Bonci D., Sala-Newby G.B., Addis R., et al. Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation 2011, 123:282-291.
52. Li Y., Song Y.-H., Li F., Yang T., Lu Y.W., Geng Y.-J. MicroRNA-221 regulates high glucose-induced endothelial dysfunction. Biochem Biophys Res Commun 2009, 381:81-83.
53. Coleman C.B., Lightell D.J., Moss S.C., Bates M., Parrino P.E., Woods T.C. Elevation of miR-221 and -222 in the internal mammary arteries of diabetic subjects and normalization with metformin. Mol Cell Endocrinol 2013, 374:125-129.
54. Togliatto G., Trombetta A., Dentelli P., Rosso A., Brizzi M.F. MIR221/MIR222-driven post-transcriptional regulation of P27KIP1 and P57KIP2 is crucial for high-glucose- and AGE-mediated vascular cell damage. Diabetologia 2011, 54:1930-1940.
55. Leung A., Trac C., Jin W., Lanting L., Akbany A., Sætrom P., et al. Novel long noncoding RNAs are regulated by angiotensin II in vascular smooth muscle cells. Circ Res 2013, 113:266-278.
56. Villeneuve L.M., Reddy M.A., Lanting L.L., Wang M., Meng L., Natarajan R. Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc Natl Acad Sci U S A 2008, 105:9047-9052.
57. Villeneuve L.M., Kato M., Reddy M.A., Wang M., Lanting L., Natarajan R. Enhanced levels of microRNA-125b in vascular smooth muscle cells of diabetic db/db mice lead to increased inflammatory gene expression by targeting the histone methyltransferase Suv39h1. Diabetes 2010, 59:2904-2915.
58. Le M.T.N., Teh C., Shyh-Chang N., Xie H., Zhou B., Korzh V., et al. MicroRNA-125b is a novel negative regulator of p53. Genes Dev 2009, 23:862-876.
59. Androulidaki A., Iliopoulos D., Arranz A., Doxaki C., Schworer S., Zacharioudaki V., et al. The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity 2009, 31:220-231.
60. Kane N.M., Thrasher A.J., Angelini G.D., Emanueli C. Concise review: MicroRNAs as modulators of stem cells and angiogenesis. Stem Cells 2014, 32:1059-1066.
61. Yiu K.-H., Tse H.-F. Specific role of impaired glucose metabolism and diabetes mellitus in endothelial progenitor cell characteristics and function. Arterioscler Thromb Vasc Biol 2014, 34:1136-1143.
62. Spinetti G., Cordella D., Fortunato O., Sangalli E., Losa S., Gotti A., et al. Global remodeling of the vascular stem cell niche in bone marrow of diabetic patients: implication of the microRNA-155/FOXO3a signaling pathway. Circ Res 2013, 112:510-522.
63. Spinetti G., Fortunato O., Caporali A., Shantikumar S., Marchetti M., Meloni M., et al. MicroRNA-15a and microRNA-16 impair human circulating proangiogenic cell functions and are increased in the proangiogenic cells and serum of patients with critical limb ischemia. Circ Res 2013, 112:335-346.
64. Caporali A., Emanueli C. MicroRNA-503 and the extended microRNA-16 family in angiogenesis. Trends Cardiovasc Med 2011, 21:162-166.
65. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008, 105:10513-10518.
66. Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18:997-1006.
67. Valadi H., Ekström K., Bossios A., Sjöstrand M., Lee J.J., Lötvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007, 9:654-659.
68. Zernecke A., Bidzhekov K., Noels H., Shagdarsuren E., Gan L., Denecke B., et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009, 2:ra81.
69. Arroyo J.D., Chevillet J.R., Kroh E.M., Ruf I.K., Pritchard C.C., Gibson D.F., et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 2011, 108:5003-5008.
70. Vickers K.C., Palmisano B.T., Shoucri B.M., Shamburek R.D., Remaley A.T. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011, 13:423-433.
71. Fang D.Y., King H.W., LI JY, Gleadle JM. Exosomes and the kidney: blaming the messenger. Nephrology 2013, 18:1-10.
72. Pegtel D.M., van de Garde M.D.B., Middeldorp J.M. Viral miRNAs exploiting the endosomal-exosomal pathway for intercellular cross-talk and immune evasion. Biochim Biophys Acta 1809, 2011:715-721.
73. Théry C., Ostrowski M., Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 2009, 9:581-593.
74. Andaloussi E.L., S, Mäger I, Breakefield XO, Wood MJA, Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov 2013, 12:347-357.
75. Lee Y., Andaloussi E.L., S, Wood MJA, Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Hum Mol Genet 2012, 21:R125-R134.
76. Malik Z.A., Kott K.S., Poe A.J., Kuo T., Chen L., Ferrara K.W., et al. Cardiac myocyte exosomes: stability, HSP60, and proteomics. Am J Physiol Heart Circ Physiol 2013, 304:H954-H965.
77. Jansen F., Yang X., Hoelscher M., Cattelan A., Schmitz T., Proebsting S., et al. Endothelial microparticle-mediated transfer of MicroRNA-126 promotes vascular endothelial cell repair via SPRED1 and is abrogated in glucose-damaged endothelial microparticles. Circulation 2013, 128:2026-2038.
78. Koga H., Sugiyama S., Kugiyama K., Watanabe K., Fukushima H., Tanaka T., et al. Elevated levels of VE-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2005, 45:1622-1630.
79. Mocharla P., Briand S., Giannotti G., Dörries C., Jakob P., Paneni F., et al. AngiomiR-126 expression and secretion from circulating CD34(+) and CD14(+) PBMCs: role for proangiogenic effects and alterations in type 2 diabetics. Blood 2013, 121:226-236.
80. Wang X., Huang W., Liu G., Cai W., Millard R.W., Wang Y., et al. Cardiomyocytes mediate anti-angiogenesis in type 2 diabetic rats through the exosomal transfer of miR-320 into endothelial cells. J Mol Cell Cardiol 2014, 74:139-150.
81. Zhang T., Lv C., Li L., Chen S., Liu S., Wang C., et al. Plasma miR-126 is a potential biomarker for early prediction of type 2 diabetes mellitus in susceptible individuals. Biomed Res Int 2013, 2013:761617.
82. Wapinski O., Chang H.Y. Long noncoding RNAs and human disease. Trends Cell Biol 2011, 21:354-361.
83. Rinn J.L., Chang H.Y. Genome regulation by long noncoding RNAs. Annu Rev Biochem 2012, 81:145-166.
84. Mercer T.R., Dinger M.E., Mattick J.S. Long non-coding RNAs: insights into functions. Nat Rev Genet 2009, 10:155-159.
85. Ponting C.P., Oliver P.L., Reik W. Evolution and functions of long noncoding RNAs. Cell 2009, 136:629-641.
86. Feng J., Bi C., Clark B.S., Mady R., Shah P., Kohtz J.D. The Evf-2 noncoding RNA is transcribed from the Dlx-5/6 ultraconserved region and functions as a Dlx-2 transcriptional coactivator. Genes Dev 2006, 20:1470-1484.
87. Martianov I., Ramadass A., Serra Barros A., Chow N., Akoulitchev A. Repression of the human dihydrofolate reductase gene by a non-coding interfering transcript. Nature 2007, 445:666-670.
88. Wang X., Arai S., Song X., Reichart D., Du K., Pascual G., et al. Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription. Nature 2008, 454:126-130.
89. Geisler S., Coller J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol 2013, 14:699-712.
90. Guttman M., Garber M., Levin J.Z., Donaghey J., Robinson J., Adiconis X., et al. Ab initio reconstruction of cell type-specific transcriptomes in mouse reveals the conserved multi-exonic structure of lincRNAs. Nat Biotechnol 2010, 28:503-510.
91. Guttman M., Amit I., Garber M., French C., Lin M.F., Feldser D., et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 2009, 458:223-227.
92. Khalil A.M., Guttman M., Huarte M., Garber M., Raj A., Rivea Morales D., et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci U S A 2009, 106:11667-11672.
93. Michalik K.M., You X., Manavski Y., Doddaballapur A., Zörnig M., Braun T., et al. Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth. Circ Res 2014, 114:1389-1397.
94. Wu G., Cai J., Han Y., Chen J., Huang Z.-P., Chen C., et al. LincRNA-p21 regulates neointima formation, vascular smooth muscle cell proliferation, apoptosis, and atherosclerosis by enhancing p53 activity. Circulation 2014, 130:1452-1465.
95. Faghihi M.A., Wahlestedt C. Regulatory roles of natural antisense transcripts. Nat Rev Mol Cell Biol 2009, 10:637-643.
96. Broadbent H.M., Peden J.F., Lorkowski S., Goel A., Ongen H., Green F., et al. Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs in the ANRIL locus on chromosome 9p. Hum Mol Genet 2008, 17:806-814.
97. Pasmant E., Sabbagh A., Vidaud M., Bièche I. ANRIL, a long, noncoding RNA, is an unexpected major hotspot in GWAS. FASEB J 2011, 25:444-448.
98. Congrains A., Kamide K., Katsuya T., Yasuda O., Oguro R., Yamamoto K., et al. CVD-associated non-coding RNA, ANRIL, modulates expression of atherogenic pathways in VSMC. Biochem Biophys Res Commun 2012, 419:612-616.
99. Louro R., Smirnova A.S., Verjovski-Almeida S. Long intronic noncoding RNA transcription: expression noise or expression choice?. Genomics 2009, 93:291-298.
100. Cheng J., Kapranov P., Drenkow J., Dike S., Brubaker S., Patel S., et al. Transcriptional maps of 10 human chromosomes at 5-nucleotide resolution. Science 2005, 308:1149-1154.
101. Pink R.C., Wicks K., Caley D.P., Punch E.K., Jacobs L., Carter D.R.F. Pseudogenes: pseudo-functional or key regulators in health and disease?. RNA 2011, 17:792-798.
102. Rackham O., Shearwood A.-M.J., Mercer T.R., Davies S.M.K., Mattick J.S., Filipovska A. Long noncoding RNAs are generated from the mitochondrial genome and regulated by nuclear-encoded proteins. RNA 2011, 17:2085-2093.
103. Kumarswamy R., Bauters C., Volkmann I., Maury F., Fetisch J., Holzmann A., et al. Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure. Circ Res 2014, 114:1569-1575.
104. Dorn G.W. LIPCAR: a mitochondrial lnc in the noncoding RNA chain?. Circ Res 2014, 114:1548-1550.
105. Bell R.D., Long X., Lin M., Bergmann J.H., Nanda V., Cowan S.L., et al. Identification and initial functional characterization of a human vascular cell-enriched long noncoding RNA. Arterioscler Thromb Vasc Biol 2014, 34:1249-1259.
106. Marrero M.B., Fulton D., Stepp D., Stern D.M. Angiotensin II-induced signaling pathways in diabetes. Curr Diabetes Rev 2005, 1:197-202.
107. Vigetti D., Deleonibus S., Moretto P., Bowen T., Fischer J.W., Grandoch M., et al. Natural antisense transcript for hyaluronan synthase 2 (HAS2-AS1) induces transcription of HAS2 via protein O-GlcNAcylation. J Biol Chem 2014, 289:28816-28826.
108. Heath J.M., Sun Y., Yuan K., Bradley W.E., Litovsky S., Dell'Italia L.J., et al. Activation of AKT by O-linked N-acetylglucosamine induces vascular calcification in diabetes mellitus. Circ Res 2014, 114:1094-1102.
109. Ding G.-L., Wang F.-F., Shu J., Tian S., Jiang Y., Zhang D., et al. Transgenerational glucose intolerance with Igf2/H19 epigenetic alterations in mouse islet induced by intrauterine hyperglycemia. Diabetes 2012, 61:1133-1142.
110. Morán I., Akerman I., van de Bunt M., Xie R., Benazra M., Nammo T., et al. Human β cell transcriptome analysis uncovers lncRNAs that are tissue-specific, dynamically regulated, and abnormally expressed in type 2 diabetes. Cell Metab 2012, 16:435-448.
111. Kornfeld J.-W., Brüning J.C. Regulation of metabolism by long, non-coding RNAs. Front Genet 2014, 5:57.
112. Ellis B.C., Graham L.D., Molloy P.L. CRNDE, a long non-coding RNA responsive to insulin/IGF signaling, regulates genes involved in central metabolism. Biochim Biophys Acta 1843, 2014:372-386.
113. Mitić T., Emanueli C. Diabetes-induced epigenetic signature in vascular cells. Endocr Metab Immune Disord Drug Targets 2012, 12:107-117.
114. Saif J., Emanueli C. MicroRNAs in post-ischemic angiogenesis and vascular remodeling. Biochem Soc Trans 2014, 42(6):1629-1636.
115. Janssen H.L.A., Reesink H.W., Lawitz E.J., Zeuzem S., Rodriguez-Torres M., Patel K., et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013, 368:1685-1694.
116. Wheeler T.M., Leger A.J., Pandey S.K., MacLeod A.R., Nakamori M., Cheng S.H., et al. Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 2012, 488:111-115.
117. Chistiakov D.A., Chekhonin V.P. Extracellular vesicles shed by glioma cells: pathogenic role and clinical value. Tumour Biol 2014, 35:8425-8438.